比利时子宫癌的实践模式、时间趋势与医疗质量:基于EFFECT数据库的分析
基于比利时EFFECT数据库2012-2016年4178例子宫癌患者,评估医疗质量指标及实践趋势。微创手术在临床I期子宫内膜癌手术患者中占61.6%,从2012年52.9%升至2016年66.4%;至少盆腔淋巴结分期在临床I期高级别子宫内膜癌中占69.0%,在临床I-II期浆液性癌、透明细胞癌或癌肉瘤中占63.9%(从2012年48.8%升至2016年77.2%)。作者认为比利时子宫癌总体医疗质量良好,但微创手术、全面手术分期和辅助治疗仍有改进空间。
要点
- 微创手术在临床I期子宫内膜癌手术患者中占61.6%,从2012年52.9%升至2016年66.4%。
- 至少盆腔淋巴结分期在临床I期高级别子宫内膜癌中占69.0%,在临床I-II期浆液性癌、透明细胞癌或癌肉瘤中占63.9%。
- 术后未行淋巴结分期的病理I期中高危或高危复发风险子宫内膜癌患者中,33.5%接受辅助放疗。
核心结论
- 研究结果表明比利时子宫癌患者总体医疗质量良好。
- 微创手术、全面手术分期和辅助治疗是可能有改进空间的治疗领域,这证实了子宫癌治疗中仍存在的争议和进一步研究的需要。
研究设计与样本
- 使用EFFECT数据库测量质量指标,纳入2012-2016年诊断为子宫癌的4178例患者。
- 采用多变量logistic混合回归检验质量指标与诊断年份之间的关联,并校正潜在混杂因素和组内相关性。
主要发现
- 在因临床I期子宫内膜癌接受手术的患者中,61.6%应用微创手术(腹腔镜或机器人辅助),从2012年52.9%升至2016年66.4%。
- 在临床I期高级别子宫内膜癌患者中,69.0%至少行盆腔淋巴结分期。
- 在临床I-II期浆液性癌、透明细胞癌或癌肉瘤患者中,63.9%至少行盆腔淋巴结分期,从2012年48.8%升至2016年77.2%。
- 在因病理I期高中危或高危复发风险子宫内膜癌接受手术且未行淋巴结分期的患者中,33.5%接受辅助放疗(外照射和/或近距离放疗)。
- 在病理III-IVA期子宫内膜癌患者中,64.4%接受辅助化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the practice patterns and quality of care for uterine cancer on a national level in Belgium, including trends in practice over the period 2012-2016. METHODS: Quality indicators were measured using the EFFectiveness of Endometrial Cancer Treatment (EFFECT) database. Multivariable logistic mixed regression was used to test for associations between the quality indicators and year of diagnosis, adjusted for potential confounders and intra-cluster correlations. RESULTS: The EFFECT database includes 4178 patients diagnosed with uterine cancer in the period 2012-2016. Minimally invasive surgery (laparoscopic or robotic-assisted) was applied in 61.6% of patients who had surgery for clinical stage I endometrial carcinoma (EC), increasing from 52.9% in 2012 to 66.4% in 2016. At least pelvic lymph node staging was performed in 69.0% of patients with clinical stage I, high-grade EC; and in 63.9% of patients with clinical stage I-II serous carcinoma, clear cell carcinoma or carcinosarcoma. The latter increased from 48.8% in 2012 to 77.2% in 2016. Adjuvant radiotherapy (external beam and/or brachytherapy) was offered to 33.5% of patients who had surgery without lymph node staging for pathological stage I EC at high-intermediate or high risk of recurrence. Adjuvant chemotherapy was administered to 64.4% of patients with pathological stage III-IVA EC. CONCLUSIONS: Study results indicate an overall good quality of care for patients with uterine cancer in Belgium. Treatment areas with potential room for improvement include the use of minimally invasive surgery, comprehensive surgical staging and adjuvant therapy, which confirms the remaining controversies in uterine cancer treatment and the need for further research.
引用
- Vanbraband J, Van Damme N, Silversmit G, et al. Practice patterns, time trends and quality of care of uterine cancer in Belgium: An analysis of the EFFECT database. Gynecol Oncol. 2023. PMID: 38086166. doi:10.1016/j.ygyno.2023.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。